Literature DB >> 24261888

Future treatment strategies for novel Middle East respiratory syndrome coronavirus infection.

Adeyemi O Adedeji1, Stefan G Sarafianos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24261888      PMCID： PMC4085789          DOI： 10.4155/fmc.13.183

Source DB:  PubMed          Journal:  Future Med Chem        ISSN： 1756-8919            Impact factor:   3.808


× No keyword cloud information.
  23 in total

1.  Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry.

Authors:  Graham Simmons; Dhaval N Gosalia; Andrew J Rennekamp; Jacqueline D Reeves; Scott L Diamond; Paul Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-04       Impact factor: 11.205

2.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

3.  Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area.

Authors:  Christopher M Booth; Larissa M Matukas; George A Tomlinson; Anita R Rachlis; David B Rose; Hy A Dwosh; Sharon L Walmsley; Tony Mazzulli; Monica Avendano; Peter Derkach; Issa E Ephtimios; Ian Kitai; Barbara D Mederski; Steven B Shadowitz; Wayne L Gold; Laura A Hawryluck; Elizabeth Rea; Jordan S Chenkin; David W Cescon; Susan M Poutanen; Allan S Detsky
Journal:  JAMA       Date:  2003-05-06       Impact factor: 56.272

4.  Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.

Authors:  Kamalendra Singh; Bruno Marchand; Karen A Kirby; Eleftherios Michailidis; Stefan G Sarafianos
Journal:  Viruses       Date:  2010-02-11       Impact factor: 5.048

5.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.

Authors:  Ali M Zaki; Sander van Boheemen; Theo M Bestebroer; Albert D M E Osterhaus; Ron A M Fouchier
Journal:  N Engl J Med       Date:  2012-10-17       Impact factor: 91.245

6.  Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients.

Authors:  Paul Feuerstadt; Ari L Bunim; Heriberto Garcia; Jordan J Karlitz; Hatef Massoumi; Amar J Thosani; Andrew Pellecchia; Allan W Wolkoff; Paul J Gaglio; John F Reinus
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

7.  Critics slam treatment for SARS as ineffective and perhaps dangerous.

Authors:  David Cyranoski
Journal:  Nature       Date:  2003-05-01       Impact factor: 49.962

8.  Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans.

Authors:  Sander van Boheemen; Miranda de Graaf; Chris Lauber; Theo M Bestebroer; V Stalin Raj; Ali Moh Zaki; Albert D M E Osterhaus; Bart L Haagmans; Alexander E Gorbalenya; Eric J Snijder; Ron A M Fouchier
Journal:  MBio       Date:  2012-11-20       Impact factor: 7.867

9.  Treatment of SARS with human interferons.

Authors:  J Cinatl; B Morgenstern; G Bauer; P Chandra; H Rabenau; H W Doerr
Journal:  Lancet       Date:  2003-07-26       Impact factor: 79.321

10.  Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus.

Authors:  J Cinatl; B Morgenstern; G Bauer; P Chandra; H Rabenau; H W Doerr
Journal:  Lancet       Date:  2003-06-14       Impact factor: 79.321
View more
  5 in total

1.  Evaluation of SSYA10-001 as a replication inhibitor of severe acute respiratory syndrome, mouse hepatitis, and Middle East respiratory syndrome coronaviruses.

Authors:  Adeyemi O Adedeji; Kamalendra Singh; Ademola Kassim; Christopher M Coleman; Ruth Elliott; Susan R Weiss; Matthew B Frieman; Stefan G Sarafianos
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

Review 2.  Middle East Respiratory Syndrome (MERS) Virus-Pathophysiological Axis and the Current Treatment Strategies.

Authors:  Abdullah M Alnuqaydan; Abdulmajeed G Almutary; Arulmalar Sukamaran; Brian Tay Wei Yang; Xiao Ting Lee; Wei Xuan Lim; Yee Min Ng; Rania Ibrahim; Thiviya Darmarajan; Satheeshkumar Nanjappan; Jestin Chellian; Mayuren Candasamy; Thiagarajan Madheswaran; Ankur Sharma; Harish Dureja; Parteek Prasher; Nitin Verma; Deepak Kumar; Kishneth Palaniveloo; Dheeraj Bisht; Gaurav Gupta; Jyotsana R Madan; Sachin Kumar Singh; Niraj Kumar Jha; Kamal Dua; Dinesh Kumar Chellappan
Journal:  AAPS PharmSciTech       Date:  2021-06-08       Impact factor: 3.246

Review 3.  Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV).

Authors:  Jaffar A Al-Tawfiq; Ziad A Memish
Journal:  Expert Rev Anti Infect Ther       Date:  2016-12-24       Impact factor: 5.091

Review 4.  Antiviral drugs specific for coronaviruses in preclinical development.

Authors:  Adeyemi O Adedeji; Stefan G Sarafianos
Journal:  Curr Opin Virol       Date:  2014-07-02       Impact factor: 7.090

Review 5.  Current diagnostic approaches to detect two important betacoronaviruses: Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Authors:  Zhi Xiong Chong; Winnie Pui Pui Liew; Hui Kian Ong; Chean Yeah Yong; Chong Seng Shit; Wan Yong Ho; Stephanie Y L Ng; Swee Keong Yeap
Journal:  Pathol Res Pract       Date:  2021-07-24       Impact factor: 3.250
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.